neopele: neoadjuvant pembrolizumab and lenvatinib in resectable stage iii melanoma
Published 1 year ago • 268 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:40
swog s1801: benefits of neoadjuvant immunotherapy for patients with resectable melanoma
-
2:46
neoadjuvant therapy in bulky stage iii melanoma
-
3:09
advances in utilizing neoadjuvant immunotherapy in melanoma
-
3:15
optimal neoadjuvant io in resectable stage iii melanoma: interferon gamma signature analysis
-
0:56
treating patients with melanoma who progressed on anti-pd-l1 with lenvatinib and pembrolizumab
-
5:18
neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage iii melanoma
-
1:55
neoadjuvant ipilimumab plus nivolumab in stage iii melanoma
-
3:44
neoadjuvant approaches in melanoma
-
1:13
clinical trials investigating the treatment of melanoma
-
1:00
tocilizumab with ipilimumab and nivolumab in unresectable melanoma
-
0:35
potential advantages of neoadjuvant immunotherapy for melanoma
-
2:32
neoadjuvant pembrolizumab administered before surgery improves outcomes of melanoma patients
-
1:16
neoadjuvant ipi nivo in stage iii melanoma: updates from opacin & opacin-neo
-
0:43
keynote-716: adjuvant pembrolizumab for high-risk melanoma
-
1:39
opacin and opacin-neo: neoadjuvant immunotherapy for advanced melanoma
-
10:42
what is new in melanoma?
-
2:52
opacin-neo trial rfs and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
-
2:31
neoadjuvant therapy with trametinib and dabrafenib in high risk resectable braf-mutant melanoma
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma